+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vericiguat API Market by Indication (Heart Failure Preserved Ejection Fraction, Heart Failure Reduced Ejection Fraction), End User (Ambulatory Care Centers, Cardiac Clinics, Hospital), Distribution Channel, Payer Type, Treatment Line, Patient Age - Global Forecast 2025-2030- Product Image
Vericiguat API Market by Indication (Heart Failure Preserved Ejection Fraction, Heart Failure Reduced Ejection Fraction), End User (Ambulatory Care Centers, Cardiac Clinics, Hospital), Distribution Channel, Payer Type, Treatment Line, Patient Age - Global Forecast 2025-2030- Product Image
New

Vericiguat API Market by Indication (Heart Failure Preserved Ejection Fraction, Heart Failure Reduced Ejection Fraction), End User (Ambulatory Care Centers, Cardiac Clinics, Hospital), Distribution Channel, Payer Type, Treatment Line, Patient Age - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6151707
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Opening the Next Chapter in Cardiovascular Therapeutics with Vericiguat API as an Emerging Pillar in Heart Failure Management and Innovation

Vericiguat, a soluble guanylate cyclase stimulator, represents a significant advancement in the management of heart failure by targeting the nitric oxide-sGC-cGMP pathway to enhance myocardial performance and vascular function. Following rigorous clinical evaluation and regulatory approval, this API has drawn considerable attention from pharmaceutical innovators, contract manufacturers, and healthcare stakeholders seeking durable treatment options for patients with chronic heart failure. This introduction underscores the relevance of Vericiguat API within the landscape of cardiovascular therapeutics, highlighting its unique mechanism of action and potential to address unmet clinical needs.

As the field of heart failure evolves, so too does the imperative for strategic intelligence to guide development, manufacturing, and commercialization decisions. This executive summary synthesizes regulatory trends, scientific breakthroughs, and market dynamics to provide a coherent framework for understanding how Vericiguat API fits into expanded treatment paradigms. By offering a clear perspective on supply chain considerations, competitive positioning, and emerging opportunities, this analysis lays the groundwork for informed decision-making among stakeholders across the value chain.

Disruptive Shifts Redefining the Vericiguat API Landscape Driven by Regulatory Evolution, Technological Breakthroughs, and Evolving Patient Care Paradigms

Recent shifts in the cardiovascular space have redefined expectations for active pharmaceutical ingredients, with Vericiguat API at the forefront of those transformations. Regulatory authorities have tightened quality expectations and accelerated pathways for therapies that address high unmet need, prompting developers to invest heavily in process optimization and robust quality systems. At the same time, the adoption of precision medicine approaches has stimulated interest in refining patient selection and dosing strategies based on hemodynamic and biomarker profiling, placing greater emphasis on the purity and consistency of the API.

Parallel to regulatory evolution, technological breakthroughs in continuous manufacturing and single-use systems have unlocked new efficiencies, reducing manufacturing footprints and enabling more flexible scale-up strategies. These advances dovetail with heightened attention to supply chain resilience, where exposure to geopolitical tensions has accelerated partnerships between originators and contract manufacturing organizations that can offer dual-sourcing capabilities across multiple geographies. In turn, these shifts have catalyzed a reconfiguration of logistics networks, with strategic warehousing and regional production hubs mitigating potential disruptions while ensuring uninterrupted patient access to Vericiguat API.

Assessing How US Tariff Adjustments in 2025 Are Poised to Reshape Sourcing, Manufacturing Costs, and Global Supply Chain Dynamics for Vericiguat API

In 2025, revisions to United States tariff schedules targeting pharmaceutical intermediates introduced new considerations for cost management and supply reliability. Raised duties on select organometallic reagents and solvent carriers have directly influenced the landed cost of Vericiguat API, prompting manufacturers to reassess sourcing strategies for raw materials and catalysts. This realignment has driven exploration of alternative feedstocks and process intensification methods to offset tariff-induced input cost escalation.

To navigate these trade policy changes, industry participants have accelerated efforts to localize critical portions of their supply chains. Nearshoring key synthetic steps to North American facilities has emerged as a viable tactic to minimize exposure to import duties and compress lead times. Concurrently, companies are engaging in proactive tariff mitigation planning, leveraging tariff classification reviews and pursuing eligible duty drawback programs. This proactive posture not only protects margins but also strengthens supply chain predictability, ensuring continuity of Vericiguat API supply for both clinical programs and commercial distribution.

Unveiling Critical Market Dimensions through a Multilayered Segmentation Framework Illuminating Indication, End User, Distribution, Payer, Treatment Line, and Patient Age

A nuanced understanding of the Vericiguat API market hinges on dissecting demand drivers across multiple dimensions. When examining indication, patients with heart failure and preserved ejection fraction command attention as a growing cohort, while those with reduced ejection fraction are stratified further into New York Heart Association Classes II, III, and IV, each presenting distinct clinical severity and therapeutic priorities that influence API formulation requirements and dosage strength optimization. This segmentation by clinical profile informs both research focus and supply forecasting.

End users span ambulatory care centers that manage early-stage heart failure interventions through outpatient dosing programs, specialized cardiac clinics that integrate Vericiguat API into advanced treatment regimens, acute and tertiary hospitals that administer intravenous-to-oral transition protocols, and specialty pharmacies that cater to complex therapy adherence needs. Each care setting drives unique packaging, delivery, and patient support service considerations, shaping distribution models and quality control checkpoints.

Distribution channels further delineate market pathways, with hospital pharmacies facilitating direct point-of-care dispensing, online pharmacies offering home delivery solutions for stable chronic therapy, and retail pharmacies providing convenient access for maintenance dosing. The distribution mix impacts inventory turn rates, cold-chain logistics requirements, and digital tracking systems deployed to maintain product integrity.

Payer type segmentation reveals differential reimbursement scenarios under government insurance plans, including Medicaid and Medicare, versus private insurance offerings where copayment structures and formulary placement influence prescribing behavior. Understanding the nuances of each coverage model is critical for pricing strategies, market access negotiations, and value demonstration efforts.

Treatment line segmentation differentiates opportunities for Vericiguat API across initial therapy protocols, second-line adjustments following suboptimal response to standard regimens, and later-line interventions in patients requiring combination therapy, compounding the need for flexible supply contracts and dose variation. Finally, patient age cohorts, spanning adult and geriatric populations, carry divergent pharmacokinetic and adherence considerations that inform dosage form decisions and stability requirements to meet diverse demographic needs.

Navigating Regional Variances Illuminates Strategic Opportunities across the Americas, Europe Middle East and Africa, and Asia Pacific in Vericiguat API Deployment

Regional nuances play a pivotal role in shaping Vericiguat API strategy. In the Americas, established regulatory pathways and advanced manufacturing infrastructure support swift clinical-to-commercial transitions, while a competitive landscape encourages process innovation and supply chain consolidation. North America’s strong emphasis on patient registries and outcomes data underpins value-based contracting discussions that inform API demand forecasts.

In Europe, the Middle East and Africa region, heterogeneous regulatory requirements and variable reimbursement frameworks necessitate adaptive market access strategies. Centralized European Medicines Agency guidance coexists with localized health technology assessments, prompting tailored dossier submissions. Meanwhile, Middle Eastern and African markets exhibit emerging demand driven by increasing cardiovascular disease prevalence, yet they require structured partnerships to navigate import controls and distribution networks.

Asia Pacific presents a complex ecosystem of rapidly expanding patient populations, evolving domestic manufacturing capabilities, and dynamic regulatory reforms. Leading markets such as Japan and Australia maintain stringent good manufacturing practice standards, creating opportunities for high-quality API suppliers. Meanwhile, Southeast Asian markets are investing in regional API hubs to service growing demand, creating supply chain synergies that companies can leverage through strategic alliances.

Profiling Leading Innovators and Collaborators Driving Vericiguat API Development through Strategic Partnerships and Technological Differentiation

Bayer AG leads the originator landscape as the developer of Vericiguat, maintaining strategic oversight of process development, regulatory filings, and lifecycle management. The company’s commitment to continuous improvement programs ensures consistent API quality and supports global supply expansion. Collaborations with academic institutions further drive early-stage innovation in route of synthesis and formulation.

Merck & Co. and Novartis AG, both with extensive cardiovascular portfolios, are exploring co-development and licensing models that could integrate Vericiguat API into broader combination therapies. Their respective investments in precision dosing technologies and digital health platforms signal a growing trend toward integrated care delivery, where API attributes must align with advanced drug-device combination solutions.

Contract development and manufacturing organizations such as Lonza, Catalent, and Thermo Fisher Scientific play an increasingly critical role by offering end-to-end development capabilities, from process optimization and scale-up to clinical trial production and commercial supply. Their investments in modular facilities and single-use technologies reduce time to market and lower capital expenditures, making them preferred partners for both originators and emerging biotech firms seeking reliable Vericiguat API supply.

Strategic Imperatives for Industry Stakeholders to Accelerate Vericiguat API Innovation, Optimize Supply Chains, and Capitalize on Emerging Market Dynamics

To capitalize on the expanding relevance of Vericiguat API, industry leaders should prioritize establishing dual-sourcing agreements for key starting materials to mitigate geopolitical and tariff risks. By investing in continuous flow chemistry and process analytical technology, companies can enhance yield consistency and reduce cycle times, ultimately improving margin stability. Engaging proactively with regulatory agencies to align on process validation and control strategies will preempt compliance bottlenecks and accelerate approval pathways.

Developing targeted clinical programs that focus on underserved segments-such as geriatric patients with comorbidities-will differentiate Vericiguat API offerings and support value arguments in negotiations with payers. Collaborating with digital health providers to integrate therapy adherence solutions can further strengthen patient outcomes and supply predictability. Strategic alliances with regional manufacturing hubs in Asia Pacific and selective nearshoring in North America will diversify supply risk and reduce total landed cost, ensuring resilience in the face of evolving trade policies.

Ensuring Rigor and Transparency through an Integrated Research Methodology Leveraging Comprehensive Data Sources and Expert Validation

This analysis synthesizes insights derived from a comprehensive research framework encompassing both primary and secondary data sources. Primary research included structured interviews with key opinion leaders in cardiology, supply chain executives, and regulatory affairs specialists to validate critical assumptions and uncover emerging trends. Secondary research entailed systematic reviews of peer-reviewed journals, regulatory filings, pharmacopeia standards, patent registries, and global trade databases to ensure factual rigor.

Segmentation logic was applied to dissect the market according to clinical indication, end user, distribution channel, payer type, treatment line, and patient demographics, enabling a multifaceted view of demand drivers. Each data point underwent triangulation through multiple sources to confirm accuracy. Finally, the findings were subjected to internal peer review and expert advisory board validation to guarantee methodological transparency and actionable relevance.

Concluding Insights that underscore the Strategic Relevance of Vericiguat API within the Broader Heart Failure Therapeutic Innovation Spectrum

Vericiguat API stands at the intersection of innovation, regulatory evolution, and shifting patient care paradigms, solidifying its role as a cornerstone in the heart failure therapeutic arsenal. By understanding the transformative shifts in manufacturing technologies, tariff landscapes, segmentation nuances, and regional dynamics, stakeholders can make informed strategic decisions that drive sustainable growth and patient-centric outcomes.

In conclusion, the insights presented in this report underscore the imperative for coordinated action across R&D, manufacturing, supply chain, and commercial functions. Embracing these findings will enable organizations to navigate complexity, mitigate risk, and secure competitive advantage as the Vericiguat API opportunity continues to mature.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Heart Failure Preserved Ejection Fraction
    • Heart Failure Reduced Ejection Fraction
      • New York Heart Association Class II
      • New York Heart Association Class III
      • New York Heart Association Class IV
  • End User
    • Ambulatory Care Centers
    • Cardiac Clinics
    • Hospital
    • Specialty Pharmacy
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Payer Type
    • Government Insurance
      • Medicaid
      • Medicare
    • Private Insurance
  • Treatment Line
    • First Line
    • Second Line
    • Third Line And Beyond
  • Patient Age
    • Adult
    • Geriatric
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Lonza Group Ltd.
  • Catalent, Inc.
  • Thermo Fisher Scientific Inc.
  • Aurobindo Pharma Limited
  • Siegfried Holding AG
  • Evonik Industries AG
  • Cambrex Corporation
  • Wuxi AppTec Co., Ltd.
  • Jubilant Life Sciences Limited
  • Dr. Reddy's Laboratories Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of vericiguat API with electronic health records to generate real-world evidence for heart failure outcomes
5.2. Development of machine learning algorithms leveraging vericiguat API data for personalized dosing recommendations
5.3. Automation of pharmacovigilance workflows using vericiguat API for real-time adverse event signal detection
5.4. Interoperability of vericiguat API with telehealth platforms to streamline remote heart failure patient management
5.5. Economic modeling and cost-effectiveness analysis integrating vericiguat API utilization data for payer decision making
5.6. Regulatory data exchange standards influencing vericiguat API integration into global cardiac treatment guidelines
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Vericiguat API Market, by Indication
8.1. Introduction
8.2. Heart Failure Preserved Ejection Fraction
8.3. Heart Failure Reduced Ejection Fraction
8.3.1. New York Heart Association Class II
8.3.2. New York Heart Association Class III
8.3.3. New York Heart Association Class IV
9. Vericiguat API Market, by End User
9.1. Introduction
9.2. Ambulatory Care Centers
9.3. Cardiac Clinics
9.4. Hospital
9.5. Specialty Pharmacy
10. Vericiguat API Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Vericiguat API Market, by Payer Type
11.1. Introduction
11.2. Government Insurance
11.2.1. Medicaid
11.2.2. Medicare
11.3. Private Insurance
12. Vericiguat API Market, by Treatment Line
12.1. Introduction
12.2. First Line
12.3. Second Line
12.4. Third Line And Beyond
13. Vericiguat API Market, by Patient Age
13.1. Introduction
13.2. Adult
13.3. Geriatric
14. Americas Vericiguat API Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Vericiguat API Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Vericiguat API Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Lonza Group Ltd.
17.3.2. Catalent, Inc.
17.3.3. Thermo Fisher Scientific Inc.
17.3.4. Aurobindo Pharma Limited
17.3.5. Siegfried Holding AG
17.3.6. Evonik Industries AG
17.3.7. Cambrex Corporation
17.3.8. Wuxi AppTec Co., Ltd.
17.3.9. Jubilant Life Sciences Limited
17.3.10. Dr. Reddy's Laboratories Limited
18. Research AI19. Research Statistics20. Research Contacts21. Research Articles22. Appendix
List of Figures
FIGURE 1. VERICIGUAT API MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL VERICIGUAT API MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL VERICIGUAT API MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL VERICIGUAT API MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL VERICIGUAT API MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL VERICIGUAT API MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL VERICIGUAT API MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 8. GLOBAL VERICIGUAT API MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS VERICIGUAT API MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS VERICIGUAT API MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES VERICIGUAT API MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES VERICIGUAT API MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC VERICIGUAT API MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC VERICIGUAT API MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. VERICIGUAT API MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. VERICIGUAT API MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. VERICIGUAT API MARKET: RESEARCHAI
FIGURE 28. VERICIGUAT API MARKET: RESEARCHSTATISTICS
FIGURE 29. VERICIGUAT API MARKET: RESEARCHCONTACTS
FIGURE 30. VERICIGUAT API MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. VERICIGUAT API MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL VERICIGUAT API MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL VERICIGUAT API MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL VERICIGUAT API MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL VERICIGUAT API MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL VERICIGUAT API MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL VERICIGUAT API MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL VERICIGUAT API MARKET SIZE, BY HEART FAILURE PRESERVED EJECTION FRACTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL VERICIGUAT API MARKET SIZE, BY HEART FAILURE PRESERVED EJECTION FRACTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL VERICIGUAT API MARKET SIZE, BY NEW YORK HEART ASSOCIATION CLASS II, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL VERICIGUAT API MARKET SIZE, BY NEW YORK HEART ASSOCIATION CLASS II, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL VERICIGUAT API MARKET SIZE, BY NEW YORK HEART ASSOCIATION CLASS III, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL VERICIGUAT API MARKET SIZE, BY NEW YORK HEART ASSOCIATION CLASS III, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL VERICIGUAT API MARKET SIZE, BY NEW YORK HEART ASSOCIATION CLASS IV, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL VERICIGUAT API MARKET SIZE, BY NEW YORK HEART ASSOCIATION CLASS IV, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL VERICIGUAT API MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL VERICIGUAT API MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL VERICIGUAT API MARKET SIZE, BY CARDIAC CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL VERICIGUAT API MARKET SIZE, BY CARDIAC CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL VERICIGUAT API MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL VERICIGUAT API MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL VERICIGUAT API MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL VERICIGUAT API MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL VERICIGUAT API MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL VERICIGUAT API MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL VERICIGUAT API MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL VERICIGUAT API MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL VERICIGUAT API MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL VERICIGUAT API MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL VERICIGUAT API MARKET SIZE, BY MEDICAID, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL VERICIGUAT API MARKET SIZE, BY MEDICAID, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL VERICIGUAT API MARKET SIZE, BY MEDICARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL VERICIGUAT API MARKET SIZE, BY MEDICARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL VERICIGUAT API MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL VERICIGUAT API MARKET SIZE, BY PRIVATE INSURANCE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL VERICIGUAT API MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL VERICIGUAT API MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL VERICIGUAT API MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL VERICIGUAT API MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL VERICIGUAT API MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL VERICIGUAT API MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL VERICIGUAT API MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL VERICIGUAT API MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL VERICIGUAT API MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL VERICIGUAT API MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS VERICIGUAT API MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS VERICIGUAT API MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES VERICIGUAT API MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES VERICIGUAT API MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 103. CANADA VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 104. CANADA VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 105. CANADA VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 106. CANADA VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 107. CANADA VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. CANADA VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. CANADA VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 110. CANADA VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 111. CANADA VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 112. CANADA VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 113. CANADA VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 114. CANADA VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 115. CANADA VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 116. CANADA VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 117. CANADA VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 118. CANADA VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 119. MEXICO VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. MEXICO VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. MEXICO VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 122. MEXICO VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 123. MEXICO VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. MEXICO VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. MEXICO VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. MEXICO VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. MEXICO VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 128. MEXICO VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 129. MEXICO VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 130. MEXICO VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 131. MEXICO VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 132. MEXICO VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 133. MEXICO VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 134. MEXICO VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA VERICIGUAT API MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 201. GERMANY VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. GERMANY VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. GERMANY VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 204. GERMANY VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 205. GERMANY VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 206. GERMANY VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 207. GERMANY VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. GERMANY VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. GERMANY VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 210. GERMANY VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 211. GERMANY VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 212. GERMANY VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 213. GERMANY VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 214. GERMANY VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 215. GERMANY VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 216. GERMANY VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 217. FRANCE VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 218. FRANCE VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 219. FRANCE VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 220. FRANCE VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 221. FRANCE VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. FRANCE VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. FRANCE VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. FRANCE VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. FRANCE VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 226. FRANCE VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 227. FRANCE VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 228. FRANCE VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 229. FRANCE VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 230. FRANCE VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 231. FRANCE VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 232. FRANCE VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 233. RUSSIA VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 234. RUSSIA VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 235. RUSSIA VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 236. RUSSIA VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 249. ITALY VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 250. ITALY VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 251. ITALY VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 252. ITALY VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 253. ITALY VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. ITALY VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. ITALY VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. ITALY VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. ITALY VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 258. ITALY VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 259. ITALY VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 260. ITALY VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 261. ITALY VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 262. ITALY VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 263. ITALY VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 264. ITALY VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 265. SPAIN VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 266. SPAIN VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 267. SPAIN VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 268. SPAIN VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 269. SPAIN VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 270. SPAIN VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 271. SPAIN VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. SPAIN VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. SPAIN VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 274. SPAIN VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 275. SPAIN VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 276. SPAIN VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 277. SPAIN VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 278. SPAIN VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 279. SPAIN VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 280. SPAIN VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 281. UNITED ARAB EMIRATES VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 294. UNITED ARAB EMIRATES VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 295. UNITED ARAB EMIRATES VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 296. UNITED ARAB EMIRATES VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 297. SAUDI ARABIA VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 298. SAUDI ARABIA VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 299. SAUDI ARABIA VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 300. SAUDI ARABIA VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. SAUDI ARABIA VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 304. SAUDI ARABIA VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 306. SAUDI ARABIA VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 308. SAUDI ARABIA VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 309. SAUDI ARABIA VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 310. SAUDI ARABIA VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 311. SAUDI ARABIA VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 312. SAUDI ARABIA VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 314. SOUTH AFRICA VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 315. SOUTH AFRICA VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 316. SOUTH AFRICA VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 317. SOUTH AFRICA VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 318. SOUTH AFRICA VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 319. SOUTH AFRICA VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 320. SOUTH AFRICA VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 321. SOUTH AFRICA VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 322. SOUTH AFRICA VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 323. SOUTH AFRICA VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 324. SOUTH AFRICA VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 325. SOUTH AFRICA VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 326. SOUTH AFRICA VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 327. SOUTH AFRICA VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
TABLE 328. SOUTH AFRICA VERICIGUAT API MARKET SIZE, BY PATIENT AGE, 2025-2030 (USD MILLION)
TABLE 329. DENMARK VERICIGUAT API MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 330. DENMARK VERICIGUAT API MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 331. DENMARK VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2018-2024 (USD MILLION)
TABLE 332. DENMARK VERICIGUAT API MARKET SIZE, BY HEART FAILURE REDUCED EJECTION FRACTION, 2025-2030 (USD MILLION)
TABLE 333. DENMARK VERICIGUAT API MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 334. DENMARK VERICIGUAT API MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 335. DENMARK VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 336. DENMARK VERICIGUAT API MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 337. DENMARK VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2018-2024 (USD MILLION)
TABLE 338. DENMARK VERICIGUAT API MARKET SIZE, BY PAYER TYPE, 2025-2030 (USD MILLION)
TABLE 339. DENMARK VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2018-2024 (USD MILLION)
TABLE 340. DENMARK VERICIGUAT API MARKET SIZE, BY GOVERNMENT INSURANCE, 2025-2030 (USD MILLION)
TABLE 341. DENMARK VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2018-2024 (USD MILLION)
TABLE 342. DENMARK VERICIGUAT API MARKET SIZE, BY TREATMENT LINE, 2025-2030 (USD MILLION)
TABLE 343. DENMARK VERICIGUAT API MARKET SIZE, BY PAT

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Vericiguat API Market report include:
  • Lonza Group Ltd.
  • Catalent, Inc.
  • Thermo Fisher Scientific Inc.
  • Aurobindo Pharma Limited
  • Siegfried Holding AG
  • Evonik Industries AG
  • Cambrex Corporation
  • Wuxi AppTec Co., Ltd.
  • Jubilant Life Sciences Limited
  • Dr. Reddy's Laboratories Limited

Related Topics

Related Reports

Vericiguat Tablets Market by Indication (Acute Decompensated Heart Failure, Chronic Heart Failure), End Use (Clinics, Hospitals), Distribution Channel, Therapy Type, Dosage Strength, Pack Size - Global Forecast 2025-2030 - Product Image

Vericiguat Tablets Market by Indication (Acute Decompensated Heart Failure, Chronic Heart Failure), End Use (Clinics, Hospitals), Distribution Channel, Therapy Type, Dosage Strength, Pack Size - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Single Ventricle Heart Disease Pipeline Analysis Report 2025 - Product Image

Single Ventricle Heart Disease Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Chronic Heart Failure - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Chronic Heart Failure - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 331 Pages
  • Global
From
Heart Failure With Reduced Ejection Fraction (HFrEF) - Pipeline Insight, 2025 - Product Image

Heart Failure With Reduced Ejection Fraction (HFrEF) - Pipeline Insight, 2025

  • Drug Pipelines
  • 50 Pages
  • Global
From
Heart Failure - Pipeline Insight, 2025 - Product Image

Heart Failure - Pipeline Insight, 2025

  • Clinical Trials
  • 240 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.